The International Postdoc Initiative 2018

Reference 2018-IPD-001

Within the framework of a program on muscular dystrophies, GENETHON is initiating a project using the CRISPR/ Cas9 technologies and entitled “Giant editing: genome editing for large genes in muscular dystrophies”. For this project, Genethon recruits a post-doctoral researcher.

The Project

Dystrophin and titin are two large proteins causing muscular dystrophies. The large size of the corresponding genes impedes classical gene therapy. To circumvent this issue, this project will develop new therapeutic tools based on the CRISPR/Cas9 technology in its different forms (gene and base editing) in iPS cells and animal models.

  • Temporary 3 years position, in Evry (91), France, starting date: beginning of January 2019.
  • Application submission
  • Application deadline: 15th September 2018.

 

Reference 2018-IPD-002

For the Congenital Myopathies project, Genethon recruits a postdoctoral researcher.

The Project

Congenital myopathies are a group of inherited disorders that present at birth or early childhood with muscle weakness and often, respiratory insufficiency. The goal of this project is to develop innovative gene therapies for some of these diseases and perform preclinical studies in animal models.

  • Temporary 3 years position, in Evry (91), France, starting date: beginning of January 2019.
  • Application submission
  • Application deadline: 15th September 2018.

 

Référence 2018-IPD-003

For the « Development of novel genome editing approach to treat Duchenne muscular dystrophy » project, Genethon recruits a postdoctoral researcher.

The Project

Duchenne muscular dystrophy (DMD) is the most prevalent, genetically inherited neuromuscular disorder worldwide and affects 1 in 3500 young males. Most DMD patients become wheelchair-dependent early in life, and the gradual development of cardiac hypertrophy-a result of severe myocardial fibrosis-typically results in premature death in the first two or three decades of life. Our aim is to find alternative genome editing strategies to treat all patients regardless of their genotype. The postdoctoral researcher will lead the generation, characterization and the use of the CRISPR/Cas9 technology in vitro in immortalized myoblast of healthy and DMD patients and in vivo in mouse models.

  • Temporary 3 years position, in Evry (91), France, starting date: beginning of January 2019.
  • Application submission
  • Application deadline: 15th September 2018.